healthy subjects for comparison N18.5
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: a) healthy subjects (Group A, young people) - Age: > 18 to 30 years inclusive - written informed consent b) healthy subjects (Group B, moderate old people) - Age: > 40 to 70 years inclusive - written informed consent c) moderate old hemodialysis patients (Group C) - Age: > 40 to 70 years inclusive - written informed consent - endstage renal disease, hemodialysis therapy for at least 3 months
Exclusion criteria
Exclusion criteria: a) healthy subjects (Group A, young people) - known malignant tumor disease - impaired kidney function (eGFR 50mg/l, fever, chills) - Diabetes mellitus (HbA1c 50mg/l, fever, chills) - Diabetes mellitus (HbA1c 50mg/l, fever, chills) - Diabetes mellitus (HbA1c < 40 mmol/mol IFCC) - psychiatric or neurological illnesses that impair the ability to consent - known pregnancy or lack of contraception (premenopausal women)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is to examine the difference in AGE-contaminated transport proteins between hemodialysis patients and an age-matched group of healthy volunteers. The evaluation is carried out using descriptive statistics and correlation respectively. | — |
Secondary
| Measure | Time frame |
|---|---|
| The following are taken into account as secondary endpoints: - difference in AGE-contaminated transport proteins in the healthy control group compared to a younger control group - correlation of AGE concentrations with parameters of the inflammatory/anti-inflammatory axis (IL-6, IL-10) - influence of AGE exposure on the regulation of the inflammatory cascade (measurement of microRNAs: miR-142-3p and miR-142-5p) - differences in bioelectrically determined nutritional parameters between the examined groups - correlation of bioelectrical impedance analysis with the AGE load of the transport proteins and the inflammatory markers. | — |
Countries
Germany
Contacts
Martin-Luther-Universität Halle-Wittenberg, Universitätsmedizin Halle, Klinik für Innere Medizin II